ROIVANT SCIENCES LTD (ROIV) Stock News

USA - NASDAQ:ROIV - BMG762791017 - Common Stock

20.775 USD

+0.15 (+0.75%)

Last: 11/10/2025, 11:37:03 AM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ROIV Latest News, Press Relases and Analysis

All

Press Releases

3 hours ago - By: Zacks Investment Research - Mentions: BFRI

Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Lags Revenue Estimates

5 hours ago - By: Roivant Sciences

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

5 hours ago - By: Roivant Sciences

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

5 days ago - By: Zacks Investment Research - Mentions: LENZ

LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Beats Revenue Estimates

14 days ago - By: Roivant Sciences

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

2 months ago - By: Benzinga

6 Analysts Assess Roivant Sciences: What You Need To Know

6 hours ago - By: Benzinga - Mentions: OGN TACT IMDX QRHC ...

Earnings Scheduled For November 10, 2025

14 days ago - By: Roivant Sciences

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025

2 months ago - By: Stocktwits - Mentions: VFMO PKW GM

Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17

2 months ago - By: The Motley Fool

Why Roivant Sciences Stock Is Soaring Today

2 months ago - By: Investor's Business Daily - Mentions: AAPL

Roivant Leaps Into A Profit-Taking Zone, Stoked By Promise In Autoimmune Disease

2 months ago - By: Roivant Sciences

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

2 months ago - By: Roivant Sciences

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

2 months ago - By: Roivant Sciences

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

2 months ago - By: Roivant Sciences

Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List

2 months ago - By: Pulmovant, Inc.

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

2 months ago - By: Roivant Sciences

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

2 months ago - By: Roivant Sciences

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

2 months ago - By: Yahoo Finance - Mentions: IMVT

Roivant Sciences (ROIV) Announces Q1 2025 Business Update

3 months ago - By: Yahoo Finance

Why Roivant Sciences Stock Bounced Back on Tuesday

3 months ago - By: The Motley Fool

Why Roivant Sciences Stock Bounced Back on Tuesday

3 months ago - By: Yahoo Finance

Why Roivant Sciences Stock Was Slipping on Monday

3 months ago - By: Yahoo Finance - Mentions: ABX UBS TSLA EA ...

Stock Market Today: S&P 500 upgraded by Citi, UBS

3 months ago - By: Zacks Investment Research - Mentions: FENC

Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates

3 months ago - By: Roivant Sciences

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

3 months ago - By: Roivant Sciences

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

3 months ago - By: Zacks Investment Research - Mentions: KURA

Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: Zacks Investment Research - Mentions: RYTM

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates